Enobia Pharma's Series D Round

Enobia Pharma raised a round of funding on August 11, 2011.

Enobia Pharma develops therapies to treat serious genetic bone disorders for which there are no approved treatments. The company's lead product, ENB-0040 (human recombinant tissue non-specific alkalin…

Articles about Enobia Pharma's Series D Round: